CLL-derived EVs activate the AKT survival pathway in stromal cells, in turn releasing vascular endothelial growth factor (VEGF), thereby contributing to tumor survival [139]. This evidence concerns the gene VEGFA and B-cell chronic lymphocytic leukemia.